Afternoon session [Active stocks and traded stocks]

*Research Pharmaceuticals <4521> 4579 +147 Share Buyback with a limit of 4.52% of issued Stocks. A cancellation of Shares will also be implemented. *Yonkyo <9955> 2219 +118 The frequency of the Shareholder benefit program will be changed from once a year to twice a year. *Amekaze Taiyo <5616> 1083 +150 A partial amendment of the Articles of Incorporation to expand and diversify business areas. *Nichireki G <5011> 2270 +92 Announcement of a Share Buyback with a limit of 3.40% of issued Stocks. *Adish <7093>

Fisco Japan36minutes ago

Alpha Purchase - Continuous profit growth for 10 consecutive periods with a large corporate customer base, turning negative factors into positives.

For the fiscal year ending December 2024, the revenue from the MRO Business accounts for about 74%, while the rest is made up by the FM Business and QITABANKUAI. The breakdown of the MRO Business consists largely of manufacturing, Construction, and service/Retail Trade, with direct sales to large enterprises exceeding 80%. The remainder consists of resale for small and medium-sized businesses (revenue through Askul). The main group of customers comprises large companies listed on the Main Board, with the customer cancellation rate for direct sales to large enterprises being nearly 0%, making it a stock-type Business.

Fisco Japan01:19 ET

The physician-led phase 1 trial of Nano mRNA---3Q TUG1 ASO (glioblastoma) is proceeding smoothly.

On the 14th, NANO MRNA (4571) announced its consolidated financial results for the third quarter of the fiscal year ending March 2025 (April-December 2024). Revenue was 0.083 billion yen, a 20.3% decrease compared to the same period last year, operating loss was 0.485 billion yen (compared to a loss of 0.687 billion yen in the same period last year), recurring loss was 0.446 billion yen (compared to a loss of 0.663 billion yen in the same period last year), and net loss attributable to shareholders of the parent company was 0.595 billion yen (compared to a loss of 0.737 billion yen in the same period last year). Regarding the main research and development progress during the cumulative period of the third quarter, TUG1

Fisco Japan00:34 ET

7&iHD and others continue to rank, and it is reported that final adjustments are being made after the MBO implementation was abandoned.

7 & iHD <3382> has made the ranking (as of 10:32). There has been a significant drop. Reports indicate that final adjustments are being made to abandon the implementation of the MBO proposed by the founding family. It has been announced that Itochu, which was viewed as a strong candidate for investment, has decided not to participate, leading to uncertainty in securing funds. This seems to be the background behind the diminishing expectations for a restructuring premium associated with narrowing options. Volume change rate ranking [As of February 27, 10:32] (Average volume over the last 5 days)

Fisco Japan20:33 ET

The research drug has been ranked, announcing a Share Buyback with a limit of 4.52% of the issued shares, and will also proceed with the cancellation of shares.

Research Pharma <4521> has ranked in (as of 9:32). It continues to rise significantly. After the close of the previous day's Trade, it was announced that a Share Buyback will be conducted for 1.8 million shares, which corresponds to 4.52% of the number of outstanding Stocks (excluding own shares), with a maximum amount of 9 billion yen. The acquisition period is from February 27, 2025, to September 30. It was also announced that 1.8 million shares of its own Stocks, equivalent to 3.91% of the total number of outstanding Stocks (including own shares), will be canceled on May 30. Volume change rate ranking [February 27, 09:32]

Fisco Japan19:36 ET

February 27 [Today's Investment Strategy]

[FISCO Selected Stocks] 【Material Stocks】 Allied Telesis Holdings <6835> 259 yen (2/26) provides IT solutions. It announced a Share Buyback of 2 million shares, amounting to up to 0.5 billion yen, which corresponds to 1.86% of the issued shares. The acquisition period is from February 27 to May 31, 2025. This action is part of a flexible capital policy and shareholder returns in response to changes in the business environment. As of January 31, 2025, the shareholding of treasury shares is 2.01 million 5802.

Fisco Japan19:08 ET